[Fundamental and clinical studies on latamoxef in the perinatal period].
Fundamental and clinical studies on latamoxef (LMOX) in the perinatal period were carried out, and following results were obtained. Concentration of LMOX was showed high peak levels in maternal serum, umbilical serum and amniotic fluid. LMOX seemed to be a very transferable compound to human tissues. LMOX was administered to 28 cases of various perinatal infections. Clinical responses were excellent in 13 cases, good in 15 cases and poor in none. And 140 cases of prophylactic use in the field of perinatal period were evaluated in good. No side effect was seen and an abnormal laboratory finding, the increase of GPT, was observed in only 1 case. LMOX was a highly useful antibiotic in perinatal infections, the safe dose range of LMOX into the perinatal mothers was estimated to be 2 g/day, with the maximum safe dose being 4 g/day.
D000328:Adult; D000653:Amniotic Fluid / Q000032:analysis; D005260:Female; D005312:Fetal Blood / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008431:Maternal-Fetal Exchange; D009070:Moxalactam / Q000097:blood* / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000097:blood* / Q000188:drug therapy; D011645:Puerperal Infection / Q000097:blood* / Q000188:drug therapy; D011704:Pyelonephritis / Q000097:blood* / Q000188:drug therapy
D009070:Moxalactam